Entropy Neurodynamics
Entropy Neurodynamics is an Australian biotechnology company focused on developing novel therapies for neurological and psychiatric disorders. They leverage innovative approaches in drug development, aiming to address unmet needs in mental health and improve patient outcomes. The company is listed on the ASX and seeks to create value through its research and development pipeline.
Short position
Entropy Neurodynamics (ASX:ENP) has 0.00% of its shares on issue reported as short positions as of 5 Oct 2026, or about 6 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. ENP is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Entropy Neurodynamics (ENP) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $2.1MM (source: ASX (Markit))vs $1.6MM (source: ASX (Markit)) (FY25)
- ASX (Markit), as at 29 Sep 2026
- NPAT
- −$4.9Mvs −$5.3M (FY25)
- Yahoo Finance, as at 29 Sep 2026
- EPS (diluted)
- −$0.003vs −$0.004 (FY25)
- Yahoo Finance, as at 29 Sep 2026
- Rev YoY
- +30.0%FY
- EPS YoY
- n/aTTM
- ASX (Markit)
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 9 Oct 2026
- Gross margin
- n/a
- Operating margin
- −327.8%
- Net margin
- −235.9%
- FCF margin
- −165.5%
- ROE
- −73.1%
- ROA
- −64.7%
- FCF conversion
- n/a
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- 7.9×
- Interest cover
- −41.5×
- Cash dividends paid / net profit
- n/a
- Market cap
- $63.9M
- P/E
- n/a
- P/B
- 8.7×
Ratios use the reporting currency (AUD); market cap is in AUD. Sources: Yahoo Finance and ASX (Markit), as at 29 Sep 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY24 |
|---|---|---|---|---|
| Revenue | $2.1MM (source: ASX (Markit)) | $1.6MM (source: ASX (Markit)) | $1.1MM (source: ASX (Markit)) | $0M (source: ASX (Markit)) |
| Operating income | −$6.8M | −$6.7M | n/a | n/a |
| EBITDA | −$4.7M | −$5.3M | n/a | n/a |
| EBIT | −$4.7M | −$5.3M | n/a | n/a |
| Interest expense | $163.2K | $7.6K | n/a | n/a |
| Pretax income | −$4.9M | −$5.3M | n/a | n/a |
| Tax | $0 | $0 | n/a | n/a |
| NPAT | −$4.9M | −$5.3M | −$6.1MM (source: ASX (Markit)) | −$5.9MM (source: ASX (Markit)) |
| Net interest income | −$5.2K | −$1.8K | n/a | n/a |
| EPS basic | −$0.003 | −$0.004 | n/a | n/a |
| EPS diluted | −$0.003 | −$0.004 | n/a | n/a |
| Shares | 1.68B | 1.44B | n/a | n/a |
- ASX (Markit)
Financial reports
The company's own filings, newest first
- Appendix 4E and 2026 Annual ReportAnnual Results28 Aug 2026via asx_announcements
- Quarterly Activities Report and Appendix 4CQuarterly Report22 Jul 2026via asx_announcements
- Quarterly Activities Report and Appendix 4CQuarterly Report28 Apr 2026via asx_announcements
- Appendix 4D and Half Year Report for period 31 Dec 2025Half Year Results27 Feb 2026via asx_announcements
- Quarterly Activities Report and Appendix 4CQuarterly Report30 Jan 2026via asx_announcements
- Company PresentationFinancial Report31 Dec 2025via crawler
- September 2025 Quarterly Activities Report CorrectionQuarterly Report7 Nov 2025via asx_announcements
- Quarterly Activities Report and Appendix 4CQuarterly Report31 Oct 2025via asx_announcements
- Appendix 4E and 2025 Annual ReportAnnual Results29 Aug 2025via asx_announcements
- Quarterly Activities Report and Appendix 4CQuarterly Report31 Jul 2025via asx_announcements
Showing 10 of 25 reports